Related Experiment Videos
[Clinical evaluation of broncho-vaxom efficiency]
T Moniuszko1, A Rogalewska, S Chyrek-Borowska
1Kliniki Alergologii AM, Białymstoku.
Polski Tygodnik Lekarski (Warsaw, Poland : 1960)
|May 3, 1991
Summary
Broncho-vaxom, a bacterial lysate vaccine, effectively reduced respiratory infections in patients with asthma and chronic bronchitis. Over 50% of patients experienced fewer and less severe infections, decreasing antibiotic reliance.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Context:
- Recurrent respiratory infections pose a significant health burden.
- Allergic-infectious bronchial asthma and chronic bronchitis are common respiratory conditions.
- Bacterial lysate vaccines are used to modulate immune responses.
Purpose:
- To evaluate the clinical efficacy of Broncho-vaxom in patients with recurrent respiratory infections.
- To assess the impact of Broncho-vaxom on asthma and chronic bronchitis management.
- To determine if Broncho-vaxom can reduce the frequency and severity of respiratory infections and antibiotic use.
Summary:
- Broncho-vaxom was administered to 40 patients diagnosed with recurrent respiratory infections, allergic-infectious bronchial asthma, and chronic bronchitis.
- The treatment involved one capsule daily for the first month, followed by 10 days per month for the third, fourth, and fifth months.
- A favorable clinical effect was observed in over 50% of patients, characterized by a reduction in the number and severity of respiratory infections and decreased antibiotic consumption.
Impact:
- Broncho-vaxom demonstrated clinical efficiency in managing recurrent respiratory infections.
- The vaccine showed potential in reducing the need for antibiotic treatments in affected patients.
- These findings support the use of Broncho-vaxom as an adjunct therapy for respiratory conditions.